Mutation analysis and response to nilotinib according to baseline mutation data in 51 patients with accelerated-phase CML
| Mutation, n = 51 . | No. patients (%) . | HR (CHR+MR/NEL+RTC), no. (%) . | MCyR (CCyR+PCyR), no. (%) . |
|---|---|---|---|
| No mutation | 22 (43) | 10 (45) | 8 (36) |
| Any mutation | 29 (57) | 14 (48) | 6 (21) |
| M244V | 5 (17) | 3 (60) | 1 (20) |
| G250E | 3 (10) | 1 (33) | 1 (33) |
| Y253H | 4 (14) | 1 (25) | 0 (0) |
| T315I | 2 (7) | 1 (50) | 0 (0) |
| F317L | 3 (10) | 2 (67) | 2 (67) |
| M351T | 5 (17) | 4 (80) | 1 (20) |
| E459K | 3 (10) | 2 (67) | 0 (0) |
| All others | 10 (34) | 5 (50) | 2 (20) |
| Mutation, n = 51 . | No. patients (%) . | HR (CHR+MR/NEL+RTC), no. (%) . | MCyR (CCyR+PCyR), no. (%) . |
|---|---|---|---|
| No mutation | 22 (43) | 10 (45) | 8 (36) |
| Any mutation | 29 (57) | 14 (48) | 6 (21) |
| M244V | 5 (17) | 3 (60) | 1 (20) |
| G250E | 3 (10) | 1 (33) | 1 (33) |
| Y253H | 4 (14) | 1 (25) | 0 (0) |
| T315I | 2 (7) | 1 (50) | 0 (0) |
| F317L | 3 (10) | 2 (67) | 2 (67) |
| M351T | 5 (17) | 4 (80) | 1 (20) |
| E459K | 3 (10) | 2 (67) | 0 (0) |
| All others | 10 (34) | 5 (50) | 2 (20) |
Of the mutations listed, only G250E and Y253H lie within the P-loop. Mutations at baseline include mutations assessed on or before day 1 prior to study drug administration. Response data are assessed within 6 months of treatment. All mutations observed only once in this group are captured in the category “All others.”